KRT6A (Keratin, type II cytoskeletal 6A) variants and mutations
KRT6A (also known as Keratin, type II cytoskeletal 6A) is a human protein-coding gene encoding a keratin, type II cytoskeletal 6A protein. It is induced in palmoplantar, nail-bed, and wound-response epithelia and helps reinforce keratinocytes under mechanical stress. Dominant pathogenic variants cause pachyonychia congenita, often with severe painful plantar keratoderma and nail dystrophy. This analysis covers 1,065 KRT6A variants and mutations. Of these, 80% have computational variant effect predictions. Disease context includes pachyonychia congenita, pachyonychia congenita 1, and hereditary disease. Example KRT6A variants include A2T, S3N, and T4A.
Variant analysis overview
- Gene: KRT6A
- Protein: Keratin, type II cytoskeletal 6A
- UniProt accession: P02538
- Organism: Homo sapiens
- Variants analyzed: 1065
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 828 unspecified-consequence records; 1 stop retained variant; 109 missense variants; 108 synonymous variants; 9 frameshift variants; 2 in-frame deletions; 5 splice-region variants; 4 stop-gained variants; 1 substitution
- Prediction scores: 849 variants have prediction scores (80% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: pachyonychia congenita, pachyonychia congenita 1, hereditary disease, skin disorder, basal cell carcinoma, skin cancer, non-melanoma skin carcinoma, common wart, skin neoplasm, non-small cell lung carcinoma, psoriasis, lung adenocarcinoma.
Protein structure and variant hotspots
- Protein features: 1 domains; 1 post-translational modification sites.
- Structural context: 613 variants have structural context.
- PTM context: 1 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable KRT6A variants
Examples include A2T, S3N, T4A, T4I, S5A, S5C, S5F, T6I. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2T (p.Ala2Thr), TOPMed rs1229026357, gnomAD rs1229026357, REVEL 0.22, CADD 8.09
- S3N (p.Ser3Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T4A (p.Thr4Ala), TOPMed rs1938306127
- T4I (p.Thr4Ile), Ensembl rs2120413355
- S5A (p.Ser5Ala), NCI-TCGA Cosmic COSV5810, Variant assessed as somatic; moderate impact.
- S5C (p.Ser5Cys), 1000Genomes rs563614469, ExAC rs563614469, TOPMed rs563614469, gnomAD rs563614469, Likely benign
- S5F (p.Ser5Phe), rs563614469, ClinGen CA6582364, ClinVar RCV003932241, 1000Genomes rs563614469, REVEL 0.12, CADD 24.00, Likely benign, KRT6A-related disorder
- T6I (p.Thr6Ile), TOPMed rs899338319, REVEL 0.09, CADD 16.60
- T6P (p.Thr6Pro), Ensembl rs1592186901
- T7N (p.Thr7Asn), ExAC rs757757524, gnomAD rs757757524, REVEL 0.04, CADD 12.10
- I8L (p.Ile8Leu), ESP rs372264347, TOPMed rs372264347, gnomAD rs372264347
- I8N (p.Ile8Asn), gnomAD rs1938305741, REVEL 0.09, CADD 18.40
- I8V (p.Ile8Val), ESP rs372264347, TOPMed rs372264347, gnomAD rs372264347, REVEL 0.05, CADD 3.70
- S10G (p.Ser10Gly), Ensembl rs1938305649
- S10R (p.Ser10Arg), ESP rs369229884, ExAC rs369229884, TOPMed rs369229884, gnomAD rs369229884
- H11Y (p.His11Tyr), ExAC rs758533268, gnomAD rs758533268, REVEL 0.09, CADD 11.50
- S12G (p.Ser12Gly), 1000Genomes rs2120413233, REVEL 0.13, CADD 15.70
- S13R (p.Ser13Arg), NCI-TCGA Cosmic COSV1004, REVEL 0.07, CADD 14.70, Variant assessed as somatic; moderate impact.
- S14G (p.Ser14Gly), ExAC rs752862612, TOPMed rs752862612, gnomAD rs752862612, REVEL 0.08, CADD 14.30
- S14I (p.Ser14Ile), gnomAD rs1340135615, REVEL 0.10, CADD 17.70
- R15C (p.Arg15Cys), rs543383074, ClinGen CA6582358, ClinVar RCV004414412, 1000Genomes rs543383074, REVEL 0.11, CADD 18.40, Uncertain significance, Inborn genetic diseases
- R15H (p.Arg15His), 1000Genomes rs533157590, ExAC rs533157590, TOPMed rs533157590, gnomAD rs533157590, REVEL 0.03, CADD 6.40, Likely benign, KRT6A-related disorder
- R15L (p.Arg15Leu), rs533157590, NCI-TCGA Cosmic COSV1004, 1000Genomes rs533157590, REVEL 0.09, CADD 12.50, Likely benign
- R15S (p.Arg15Ser), NCI-TCGA Cosmic COSV1004, Variant assessed as somatic; moderate impact.
- R16P (p.Arg16Pro), ExAC rs761780446, gnomAD rs761780446
- R16Q (p.Arg16Gln), ExAC rs761780446, gnomAD rs761780446, REVEL 0.12, CADD 18.60
- R16W (p.Arg16Trp), rs767267061, ClinGen CA6582355, NCI-TCGA Cosmic COSV5810, ClinVar RCV002714703, REVEL 0.32, CADD 19.70, Uncertain significance, not provided; Inborn genetic diseases
- G17A (p.Gly17Ala), ExAC rs774212057, gnomAD rs774212057, REVEL 0.12, CADD 15.60
- G17C (p.Gly17Cys), gnomAD rs1402351179, REVEL 0.26, CADD 21.10
- G17D (p.Gly17Asp), ExAC rs774212057, gnomAD rs774212057, REVEL 0.20, CADD 20.90
- G17S (p.Gly17Ser), NCI-TCGA Cosmic COSV5810, REVEL 0.09, CADD 9.79, Variant assessed as somatic; moderate impact.
- F18L (p.Phe18Leu), gnomAD rs1456998109, REVEL 0.34, CADD 22.20
- S19N (p.Ser19Asn), rs201201647, ClinGen CA6582352, ClinVar RCV003954609, 1000Genomes rs201201647, REVEL 0.31, CADD 21.60, Likely benign, KRT6A-related disorder
- A20V (p.Ala20Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N21S (p.Asn21Ser), rs17845411, ClinGen CA6582351, ClinVar RCV001731069, ClinVar RCV003984086, REVEL 0.14, CADD 0.64, Benign, Pachyonychia congenita 3; not provided
- N21T (p.Asn21Thr), 1000Genomes rs17845411, ESP rs17845411, ExAC rs17845411, TOPMed rs17845411, REVEL 0.08, CADD 6.49, Benign
- S22* (p.Ser22Ter), NCI-TCGA Cosmic COSV9904, Variant assessed as somatic; high impact.
- A23G (p.Ala23Gly), rs1423965394, gnomAD rs1423965394, REVEL 0.47, CADD 25.40, Variant assessed as somatic; moderate impact.
- A23P (p.Ala23Pro), Ensembl rs1406917541, REVEL 0.52, CADD 24.70
- A23T (p.Ala23Thr), Ensembl rs1406917541, REVEL 0.31, CADD 24.50
- R24G (p.Arg24Gly), Ensembl rs1592186831
- R24K (p.Arg24Lys), 1000Genomes rs1244209640, TOPMed rs1244209640, gnomAD rs1244209640, REVEL 0.20, CADD 16.30
- R24S (p.Arg24Ser), TOPMed rs1938304618, REVEL 0.30, CADD 13.10
- P26R (p.Pro26Arg), gnomAD rs1289441451, REVEL 0.34, CADD 23.10
- P26S (p.Pro26Ser), ExAC rs775241916, TOPMed rs775241916, gnomAD rs775241916, REVEL 0.07, CADD 19.60
- G27E (p.Gly27Glu), rs759307145, NCI-TCGA Cosmic COSV5810, ExAC rs759307145, TOPMed rs759307145, REVEL 0.41, CADD 18.00, Variant assessed as somatic; moderate impact.
- G27R (p.Gly27Arg), gnomAD rs1240542109, REVEL 0.09, CADD 17.20
- V28A (p.Val28Ala), Ensembl rs1592186813, REVEL 0.12, CADD 3.44
- V28F (p.Val28Phe), ExAC rs771263689, gnomAD rs771263689, REVEL 0.12, CADD 7.93
- S29N (p.Ser29Asn), ExAC rs747540470
- S29R (p.Ser29Arg), ExAC rs778160585, TOPMed rs778160585, gnomAD rs778160585, REVEL 0.24, CADD 15.60, Uncertain significance, Inborn genetic diseases
- S29T (p.Ser29Thr), ExAC rs747540470
- R30C (p.Arg30Cys), 1000Genomes rs368524604, ESP rs368524604, ExAC rs368524604, TOPMed rs368524604, REVEL 0.36, CADD 24.50
- R30H (p.Arg30His), rs1308335675, NCI-TCGA Cosmic COSV5810, TOPMed rs1308335675, gnomAD rs1308335675, REVEL 0.07, CADD 16.60, Variant assessed as somatic; moderate impact.
- R30L (p.Arg30Leu), TOPMed rs1308335675, gnomAD rs1308335675, REVEL 0.23, CADD 17.00
- S31C (p.Ser31Cys), NCI-TCGA Cosmic COSV5810, Variant assessed as somatic; moderate impact.
- S31P (p.Ser31Pro), TOPMed rs921902439, gnomAD rs921902439, REVEL 0.18, CADD 13.80
- G32A (p.Gly32Ala), Ensembl rs2120412906, REVEL 0.07, CADD 19.90
- G32S (p.Gly32Ser), gnomAD rs1331987048, REVEL 0.07, CADD 13.50
- F33L (p.Phe33Leu), TOPMed rs1938303842
- F33S (p.Phe33Ser), rs1223422051, ClinGen CA384966357, ClinVar RCV002751902, gnomAD rs1223422051, REVEL 0.42, CADD 24.20, Uncertain significance, Inborn genetic diseases
- S34N (p.Ser34Asn), 1000Genomes rs555709018, ExAC rs555709018, TOPMed rs555709018, gnomAD rs555709018, REVEL 0.24, CADD 23.50
- S35G (p.Ser35Gly), gnomAD rs1387957268, REVEL 0.36, CADD 23.10
- V36I (p.Val36Ile), rs755172711, ClinGen CA6582340, ClinVar RCV000899967, 1000Genomes rs755172711, REVEL 0.01, CADD 6.53, Likely benign, not provided
- S37F (p.Ser37Phe), NCI-TCGA Cosmic COSV5810, Variant assessed as somatic; moderate impact.
- V38G (p.Val38Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V38L (p.Val38Leu), ExAC rs757013535, TOPMed rs757013535, gnomAD rs757013535, REVEL 0.09, CADD 15.70
- V38M (p.Val38Met), rs757013535, ExAC rs757013535, TOPMed rs757013535, gnomAD rs757013535, REVEL 0.21, CADD 16.30, Variant assessed as somatic; moderate impact.
- R40C (p.Arg40Cys), ESP rs375671619, ExAC rs375671619, TOPMed rs375671619, gnomAD rs375671619, REVEL 0.46, CADD 24.10
- R40H (p.Arg40His), ExAC rs762500774, TOPMed rs762500774, gnomAD rs762500774, REVEL 0.49, CADD 22.80
- R40L (p.Arg40Leu), ExAC rs762500774, TOPMed rs762500774, gnomAD rs762500774
- R42T (p.Arg42Thr), TOPMed rs1477641840
- R42W (p.Arg42Trp), ExAC rs752229219, TOPMed rs752229219, gnomAD rs752229219, REVEL 0.41, CADD 21.80
- G43D (p.Gly43Asp), ExAC rs764877666, TOPMed rs764877666, gnomAD rs764877666, REVEL 0.68, CADD 24.60
- G43V (p.Gly43Val), ExAC rs764877666, TOPMed rs764877666, gnomAD rs764877666, REVEL 0.76, CADD 24.30
- S44R (p.Ser44Arg), Ensembl rs1592186767
- G45C (p.Gly45Cys), TOPMed rs1421381314, gnomAD rs1421381314, REVEL 0.51, CADD 24.50
- G46D (p.Gly46Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G48A (p.Gly48Ala), Ensembl rs1938302192
- G49D (p.Gly49Asp), ExAC rs771272231, TOPMed rs771272231, gnomAD rs771272231, REVEL 0.43, CADD 16.30
- C51R (p.Cys51Arg), TOPMed rs1938301828, gnomAD rs1938301828, REVEL 0.41, CADD 14.00
- C51W (p.Cys51Trp), Ensembl rs1592186747
- G52R (p.Gly52Arg), NCI-TCGA Cosmic COSV5810, Variant assessed as somatic; moderate impact.
- G53E (p.Gly53Glu), NCI-TCGA Cosmic COSV5810, Variant assessed as somatic; moderate impact.
- G53V (p.Gly53Val), NCI-TCGA Cosmic COSV5810, REVEL 0.58, CADD 22.80, Variant assessed as somatic; moderate impact.
- A54D (p.Ala54Asp), TOPMed rs1232527188, gnomAD rs1232527188, REVEL 0.33, CADD 22.00
- A54G (p.Ala54Gly), TOPMed rs1232527188, gnomAD rs1232527188, Uncertain significance, Inborn genetic diseases
- A54P (p.Ala54Pro), Ensembl rs111569932
- G55A (p.Gly55Ala), TOPMed rs1272356724
- G55R (p.Gly55Arg), ESP rs374545789, ExAC rs374545789, TOPMed rs374545789, gnomAD rs374545789
- G55S (p.Gly55Ser), ESP rs374545789, ExAC rs374545789, TOPMed rs374545789, gnomAD rs374545789, REVEL 0.34, CADD 19.60
- F56L (p.Phe56Leu), Ensembl rs1592186738
- S58N (p.Ser58Asn), ExAC rs772590643, TOPMed rs772590643, gnomAD rs772590643, REVEL 0.38, CADD 23.50
- R59C (p.Arg59Cys), TOPMed rs1386817536, gnomAD rs1386817536, REVEL 0.32, CADD 24.00
- R59H (p.Arg59His), ExAC rs748703748, TOPMed rs748703748, gnomAD rs748703748, REVEL 0.12, CADD 22.90, Uncertain significance, Inborn genetic diseases
- Y62C (p.Tyr62Cys), Ensembl rs1592186720
- G65R (p.Gly65Arg), TOPMed rs1376405967, gnomAD rs1376405967, REVEL 0.45, CADD 23.50
- G65W (p.Gly65Trp), rs1376405967, TOPMed rs1376405967, gnomAD rs1376405967, REVEL 0.49, CADD 23.90, Variant assessed as somatic; moderate impact.
- G66V (p.Gly66Val), TOPMed rs928566529, REVEL 0.31, CADD 22.70
- S67P (p.Ser67Pro), Ensembl rs1592186705
- K68R (p.Lys68Arg), gnomAD rs1487839397, REVEL 0.09, CADD 15.70
- R69G (p.Arg69Gly), Ensembl rs1938300650, REVEL 0.18, CADD 23.60
- I70F (p.Ile70Phe), ExAC rs757036849, gnomAD rs757036849
- I70T (p.Ile70Thr), ExAC rs751333405, gnomAD rs751333405, REVEL 0.31, CADD 22.70
- S71C (p.Ser71Cys), Ensembl rs1938300486
- S71F (p.Ser71Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I72T (p.Ile72Thr), rs571307633, ClinGen CA6582314, ClinVar RCV002749129, 1000Genomes rs571307633, REVEL 0.15, CADD 20.50, Uncertain significance, Inborn genetic diseases
- G73* (p.Gly73Ter), gnomAD rs1489391875
- G74A (p.Gly74Ala), TOPMed rs1449780449, REVEL 0.37, CADD 15.20
- G74W (p.Gly74Trp), gnomAD rs1224623328, REVEL 0.60, CADD 24.70
- G75S (p.Gly75Ser), TOPMed rs1388503469, gnomAD rs1388503469, REVEL 0.05, CADD 16.70
- S76C (p.Ser76Cys), TOPMed rs969769444, gnomAD rs969769444, REVEL 0.12, CADD 22.80
- S76T (p.Ser76Thr), gnomAD rs1199645693, REVEL 0.02, CADD 19.90
- C77S (p.Cys77Ser), Ensembl rs1938300108
- A78V (p.Ala78Val), 1000Genomes rs557885841, ExAC rs557885841, TOPMed rs557885841, gnomAD rs557885841, REVEL 0.13, CADD 5.02
- S80I (p.Ser80Ile), NCI-TCGA Cosmic COSV1004, Variant assessed as somatic; moderate impact.
- G81V (p.Gly81Val), ExAC rs764824336, gnomAD rs764824336, REVEL 0.43, CADD 22.40
- G82S (p.Gly82Ser), rs758984854, ExAC rs758984854, TOPMed rs758984854, gnomAD rs758984854, REVEL 0.24, CADD 15.00, Uncertain significance, Inborn genetic diseases
- G84D (p.Gly84Asp), NCI-TCGA TCGA novel, TOPMed rs1938299685, REVEL 0.40, CADD 21.60, Variant assessed as somatic; moderate impact.
- R86T (p.Arg86Thr), gnomAD rs1345402703, REVEL 0.09, CADD 21.90
- A87V (p.Ala87Val), TOPMed rs1938299571
- G88R (p.Gly88Arg), rs201156103, ClinGen CA6582310, ClinVar RCV004414411, 1000Genomes rs201156103, REVEL 0.19, CADD 23.10, Conflicting interpretations, not provided; Inborn genetic diseases
- G89S (p.Gly89Ser), gnomAD rs1414229848, REVEL 0.06, CADD 20.00
- S90N (p.Ser90Asn), Ensembl rs1938299361, Uncertain significance, Inborn genetic diseases
- G92C (p.Gly92Cys), Ensembl rs1938299313
- G92V (p.Gly92Val), Ensembl rs1389879211, REVEL 0.32, CADD 21.60
- G94S (p.Gly94Ser), TOPMed rs1938299227
- G95A (p.Gly95Ala), Ensembl rs1434760041, REVEL 0.33, CADD 11.60
- A96S (p.Ala96Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A96T (p.Ala96Thr), ESP rs372112762, ExAC rs372112762, TOPMed rs372112762, gnomAD rs372112762, REVEL 0.13, CADD 12.90, Uncertain significance, Inborn genetic diseases
- G97E (p.Gly97Glu), NCI-TCGA Cosmic COSV1004, Variant assessed as somatic; moderate impact.
- G97R (p.Gly97Arg), rs200254647, NCI-TCGA Cosmic COSV5810, ExAC rs200254647, TOPMed rs200254647, REVEL 0.33, CADD 11.50, Variant assessed as somatic; moderate impact.
- S98R (p.Ser98Arg), 1000Genomes rs565853825
- G99* (p.Gly99Ter), NCI-TCGA Cosmic COSV1004, Variant assessed as somatic; high impact.
- G99E (p.Gly99Glu), NCI-TCGA Cosmic COSV5810, Variant assessed as somatic; moderate impact.
- G99R (p.Gly99Arg), NCI-TCGA Cosmic COSV1004, REVEL 0.59, CADD 22.40, Variant assessed as somatic; moderate impact.
- G101C (p.Gly101Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F102V (p.Phe102Val), TOPMed rs1191581625, gnomAD rs1191581625, REVEL 0.31, CADD 15.80
- G103C (p.Gly103Cys), 1000Genomes rs548869463, ExAC rs548869463, TOPMed rs548869463, gnomAD rs548869463, REVEL 0.50, CADD 22.60
- G103S (p.Gly103Ser), 1000Genomes rs548869463, ExAC rs548869463, TOPMed rs548869463, gnomAD rs548869463, REVEL 0.31, CADD 12.80
- G104D (p.Gly104Asp), TOPMed rs1938298350
- A106G (p.Ala106Gly), TOPMed rs1440511992, gnomAD rs1440511992, REVEL 0.04, CADD 8.41
- A106T (p.Ala106Thr), TOPMed rs1187060006, gnomAD rs1187060006, REVEL 0.04, CADD 13.40
- A106V (p.Ala106Val), TOPMed rs1440511992, gnomAD rs1440511992
- G107S (p.Gly107Ser), rs749357737, ClinGen CA6582302, NCI-TCGA Cosmic COSV5810, ClinVar RCV002659904, REVEL 0.22, CADD 12.40, Uncertain significance, Inborn genetic diseases
- I108T (p.Ile108Thr), gnomAD rs1317216341, REVEL 0.24, CADD 2.09
- G109A (p.Gly109Ala), ExAC rs769880941, TOPMed rs769880941, gnomAD rs769880941, REVEL 0.38, CADD 16.40
- G109D (p.Gly109Asp), ExAC rs769880941, TOPMed rs769880941, gnomAD rs769880941
- G111A (p.Gly111Ala), 1000Genomes rs681063, ExAC rs681063, TOPMed rs681063, gnomAD rs681063, REVEL 0.60, CADD 18.40, Uncertain significance
- G111D (p.Gly111Asp), rs681063, ClinGen CA6582298, ClinVar RCV001598427, UniProt VAR 035030, REVEL 0.69, CADD 23.70, Uncertain significance, not provided
- G111R (p.Gly111Arg), gnomAD rs1938297552, REVEL 0.72, CADD 24.00
- G113D (p.Gly113Asp), ExAC rs748044525, TOPMed rs748044525, gnomAD rs748044525, REVEL 0.72, CADD 22.40, Uncertain significance, Inborn genetic diseases
- G115E (p.Gly115Glu), Ensembl rs2120411545, REVEL 0.75, CADD 23.40
- A116D (p.Ala116Asp), gnomAD rs1470623232, REVEL 0.53, CADD 19.50
- A116T (p.Ala116Thr), Ensembl rs2120411521, REVEL 0.29, CADD 14.60
- G117D (p.Gly117Asp), TOPMed rs1411763179, gnomAD rs1411763179, REVEL 0.78, CADD 23.10
- G117S (p.Gly117Ser), ExAC rs754474806, TOPMed rs754474806, gnomAD rs754474806, REVEL 0.73, CADD 23.30
- G117V (p.Gly117Val), TOPMed rs1411763179, gnomAD rs1411763179, REVEL 0.77, CADD 24.00
- A119T (p.Ala119Thr), Ensembl rs2120411439
- G120C (p.Gly120Cys), TOPMed rs1938296666, REVEL 0.46, CADD 24.60
- G120V (p.Gly120Val), rs2498495339, ClinGen CA384964501, ClinVar RCV002821363, Uncertain significance, Inborn genetic diseases
- G121S (p.Gly121Ser), rs753315066, ClinGen CA6582293, ClinVar RCV002644705, ExAC rs753315066, REVEL 0.66, CADD 23.60, Uncertain significance, Inborn genetic diseases
- F122S (p.Phe122Ser), rs549671322, ClinGen CA6582291, ClinVar RCV003245754, 1000Genomes rs549671322, REVEL 0.17, CADD 9.18, Uncertain significance, Inborn genetic diseases
- G123E (p.Gly123Glu), ExAC rs767856687, TOPMed rs767856687, gnomAD rs767856687, REVEL 0.71, CADD 24.80
- G123R (p.Gly123Arg), ExAC rs750145364, TOPMed rs750145364, gnomAD rs750145364, REVEL 0.66, CADD 24.10
- G124D (p.Gly124Asp), rs762168782, NCI-TCGA Cosmic COSV1004, ExAC rs762168782, TOPMed rs762168782, REVEL 0.47, CADD 22.50, Variant assessed as somatic; moderate impact.
- P125L (p.Pro125Leu), rs774798543, ClinGen CA6582287, ClinVar RCV002891743, ExAC rs774798543, REVEL 0.28, CADD 19.90, Uncertain significance, Inborn genetic diseases
- P125S (p.Pro125Ser), TOPMed rs1938296007
- P128L (p.Pro128Leu), gnomAD rs1938295486, REVEL 0.42, CADD 23.70
- P128S (p.Pro128Ser), rs1339399303, TOPMed rs1339399303, gnomAD rs1339399303, REVEL 0.12, CADD 22.50, Variant assessed as somatic; moderate impact.
- V129L (p.Val129Leu), TOPMed rs1358014273, gnomAD rs1358014273, REVEL 0.42, CADD 21.70, Uncertain significance, Inborn genetic diseases
- C130* (p.Cys130Ter), ExAC rs777003645, gnomAD rs777003645, CADD 37.00
- C130F (p.Cys130Phe), ExAC rs746061780, TOPMed rs746061780, gnomAD rs746061780, REVEL 0.59, CADD 25.60
- C130Y (p.Cys130Tyr), ExAC rs746061780, TOPMed rs746061780, gnomAD rs746061780, REVEL 0.57, CADD 25.50, Uncertain significance, Inborn genetic diseases
- P131L (p.Pro131Leu), ExAC rs771929106, gnomAD rs771929106, REVEL 0.69, CADD 26.80
- P131S (p.Pro131Ser), rs1376577077, NCI-TCGA Cosmic COSV1004, TOPMed rs1376577077, gnomAD rs1376577077, REVEL 0.46, CADD 25.30, Variant assessed as somatic; moderate impact.
- P131T (p.Pro131Thr), rs1376577077, ClinGen CA384964346, ClinVar RCV002845329, REVEL 0.45, CADD 24.80, Uncertain significance, Inborn genetic diseases
- P132L (p.Pro132Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- P132R (p.Pro132Arg), Ensembl rs1039481143
- P132S (p.Pro132Ser), 1000Genomes rs564186303, ExAC rs564186303, gnomAD rs564186303, REVEL 0.45, CADD 22.70
Public KRT6A analysis runs
- KRT6A analysis run — KRT6A (1,065 variants) — completed 2026-08-22